Hi-Tech Pharmacal Co., Inc. (HITK) enjoyed a strong performance from generic pharmaceuticals in its fiscal first quarter, leading to a sharp earnings surprise and large revenue growth.

< ?DART(15);?> With a gain of only around 3.8%, HITK is a top-performing Zacks #1 Rank company today. Volume is at 514,000, versus the daily average of 586,000.

HITK is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. It specializes in difficult-to-manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products.

The company is part of the Medical-Generic Drugs industry. There is only 1 other name from that space on today's 218-stock Zacks #1 Rank List, and that is Impax Laboratories, Inc. (IPXL).

Strong Fiscal First Quarter

In early September, HITK released its fiscal first quarter report, which included earnings per

...

Cornerstone Therapeutics, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. The company is dedicated to making quality medicines in order to improve the quality of life.

Cornerstone offers trusted medications such as Zyflo CR®, Spectracef® and AlleRx®. Zyflo CR® is an extended release oral medication that is used to prevent and treat asthma in adults and children 12 years and older. Infections caused by bacteria can be treated with Spectracef®, while those suffering from allergies will find relief by taking AlleRx®.

Cornerstone has successfully alienated themselves from their competitors by partnering with leading domestic and international pharmaceutical companies. Through strategic planning, the company aims to maximize the potential value and competitive position of its currently marketed products, newly acquired products and product candidates that are currently in development.

Let us hear your

...

For Immediate Release

Chicago, IL - March 31, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Ness Technologies (NSTC), American Capital Agency Corp (AGNC), Biogen Idec (BIIB), Sohu.com Inc (SOHU) and Cornerstone Therapeutics Inc (CRTX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Ness Tech with More Downside

Ness Technologies (NSTC) is a small player in the IT services market. The company posted mixed 4Q08 results, with revenue below expectation but in line EPS.

The company's Application Development and Software Product Engineering segment performed very well in 4Q08. However,

...

Cornerstone Pharma Gets New Lease on LifeCornerstone Therapeutics, Inc. (CRTX) is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. Cornerstone Therapeutics is a newly created company following the merger of private Cornerstone BioPharma with public Critical Therapeutics completed on October 31, 2008. The merged company gets a new lease on life, finally.Merger Positive for Both Companies We think the merger makes sense and is positive to both old companies. For Critical Therapeutics, the merger has greatly expanded its product portfolio, provided better resources for operations and sustainable growth. Critical Therapeutics was a tiny biotech company with only one product -- Zyflo/Zyflo CR -- on the market, with a very weak pipeline. Sales of Zyflo/Zyflo CR have been slow and the company had been under great pressure to expand its portfolio.The merger with ...

Sciele Pharma (SCRX), based in Atlanta, Georgia, is a pharmaceutical company founded in 1992. The company specializes in sales, marketing and development of branded prescription products focused on the therapeutic areas of cardiovascular, diabetes, women’s health and pediatrics. Through its focus areas, the company’s products treat health issues such as hypertension, high cholesterol, and Type 2 diabetes.

The company and Addrenex Pharmaceuticals recently announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) showed statistically significant improvement over placebo. Addrenex Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes drugs to great adrenergic dysregulation. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraine and post-menopausal symptoms.

The study indicated that Clonicel achieved statistical significance on the primary endpoint, which is based on the ADHD Rating Scale of 18 symptoms

...